{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:23:59Z","timestamp":1761765839244},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/inf.0000000000000511","type":"journal-article","created":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T12:50:51Z","timestamp":1408107051000},"page":"180-185","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 Given to Healthy Infants at 2, 3, 4 and 12 Months of Age"],"prefix":"10.1097","volume":"34","author":[{"given":"Janusz","family":"Gadzinowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elzbieta","family":"Kopi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Majda-Stanis\u0142awska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Korbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek J.","family":"Pietrzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherryl A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio A.","family":"Emini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-15-20210202","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3201\/eid1106.050147","article-title":"Hidden epidemic of macrolide-resistant pneumococci.","volume":"11","author":"Klugman","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R4-15-20210202","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijantimicag.2008.01.021","article-title":"Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.","volume":"32","author":"Pletz","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R5-15-20210202","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R6-15-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R7-15-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R8-15-20210202","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1542\/peds.2009-1405","article-title":"PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.","volume":"125","author":"Bryant","year":"2010","journal-title":"Pediatrics"},{"key":"R9-15-20210202","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/CVI.00062-10","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.","volume":"17","author":"Esposito","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R10-15-20210202","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"R11-15-20210202","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R12-15-20210202","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"R13-15-20210202","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","article-title":"Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.","volume":"95","author":"Coors","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R14-15-20210202","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/S0264-410X(03)00230-5","article-title":"Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.","volume":"21","author":"Jodar","year":"2003","journal-title":"Vaccine"},{"key":"R16-15-20210202","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1081\/IMM-100105064","article-title":"A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides.","volume":"30","author":"Quataert","year":"2001","journal-title":"Immunol Invest"},{"key":"R17-15-20210202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/CDLI.12.2.287-295.2005","article-title":"Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.","volume":"12","author":"Hu","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R18-15-20210202","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CDLI.2.5.590-597.1995","article-title":"Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S.","volume":"2","author":"Quataert","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"R19-15-20210202","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1128\/CDLI.11.6.1064-1069.2004","article-title":"Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f).","volume":"11","author":"Quataert","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"R20-15-20210202","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"R21-15-20210202","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CDLI.4.4.415-422.1997","article-title":"Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.","volume":"4","author":"Romero-Steiner","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R22-15-20210202","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions.","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:05:11Z","timestamp":1620954311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201502000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000511","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}